ATE366114T1 - Verwendung von anti-prolaktin agentien zur behandlung von krebs - Google Patents

Verwendung von anti-prolaktin agentien zur behandlung von krebs

Info

Publication number
ATE366114T1
ATE366114T1 AT99921843T AT99921843T ATE366114T1 AT E366114 T1 ATE366114 T1 AT E366114T1 AT 99921843 T AT99921843 T AT 99921843T AT 99921843 T AT99921843 T AT 99921843T AT E366114 T1 ATE366114 T1 AT E366114T1
Authority
AT
Austria
Prior art keywords
prolactin
treat cancer
agents
prolactin agents
human
Prior art date
Application number
AT99921843T
Other languages
German (de)
English (en)
Inventor
Wen Y Chen
Thomas E Wagner
Original Assignee
Greenville Hospital System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26772335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366114(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Greenville Hospital System filed Critical Greenville Hospital System
Application granted granted Critical
Publication of ATE366114T1 publication Critical patent/ATE366114T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99921843T 1998-05-12 1999-05-11 Verwendung von anti-prolaktin agentien zur behandlung von krebs ATE366114T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8512898P 1998-05-12 1998-05-12
US24604199A 1999-02-05 1999-02-05

Publications (1)

Publication Number Publication Date
ATE366114T1 true ATE366114T1 (de) 2007-07-15

Family

ID=26772335

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99921843T ATE366114T1 (de) 1998-05-12 1999-05-11 Verwendung von anti-prolaktin agentien zur behandlung von krebs

Country Status (11)

Country Link
US (2) US7115556B2 (enExample)
EP (2) EP1079851B1 (enExample)
JP (4) JP5259896B2 (enExample)
AT (1) ATE366114T1 (enExample)
AU (1) AU3895299A (enExample)
CA (1) CA2328520C (enExample)
DE (1) DE69936451T2 (enExample)
DK (1) DK1079851T3 (enExample)
ES (1) ES2288777T3 (enExample)
PT (1) PT1079851E (enExample)
WO (1) WO1999058142A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404088A1 (en) * 2000-03-23 2001-09-27 Greenville Hospital System Bi-functional cancer treatment agents
US7820146B2 (en) * 2002-06-12 2010-10-26 L'oreal S.A. Care and/or make-up cosmetic composition structured with silicone polymers and organogelling agents, in rigid form
AU2003300904A1 (en) 2002-12-13 2004-07-09 The Ohio State University Antagonists for human prolactin
WO2004060299A2 (en) 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US8754031B2 (en) 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US7507716B2 (en) * 2005-07-06 2009-03-24 Board Of Regents, The University Of Texas System Method for treating pain with prolactin antagonists
WO2008028684A2 (en) * 2006-09-08 2008-03-13 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
WO2008114077A1 (en) * 2007-03-20 2008-09-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Constitutively active mutants of the prolactin receptor
EP2167116A2 (en) * 2007-07-05 2010-03-31 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
WO2009135056A2 (en) * 2008-04-30 2009-11-05 Monsanto Technology Llc Recombinant dna vectors for expression of human prolactin antagonists
US8648046B2 (en) * 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
AU2010218261B2 (en) * 2009-02-26 2015-08-20 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
US8759289B2 (en) * 2010-02-03 2014-06-24 Orbis Health Solutions Llc Method for sensitizing cancer stem cells to cancer therapy
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
WO2018102304A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833516A (en) * 1987-08-03 1989-05-23 International Business Machines Corporation High density memory cell structure having a vertical trench transistor self-aligned with a vertical trench capacitor and fabrication methods therefor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5506107A (en) * 1991-05-10 1996-04-09 Genentech, Inc. Selecting ligand agonists and antagonists
US6429186B1 (en) * 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
DE4231297A1 (de) * 1992-09-18 1994-03-24 Basf Ag Verfahren zur Herstellung von 3-(2'-Oxyethyl)-dihydro-2-(3H)furanonen
ES2180571T3 (es) 1993-02-19 2003-02-16 Genentech Inc Antagonistas de ligando para el tratamiento de cancer de mama.
PT754682E (pt) * 1994-04-06 2002-03-28 Nippon Shinyaku Co Ltd Derivado de aminostilbazol e medicamento
DE19718721C2 (de) * 1997-05-02 1999-10-07 Siemens Ag DRAM-Zellenanordnung und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
JP2013224309A (ja) 2013-10-31
US20030022833A1 (en) 2003-01-30
PT1079851E (pt) 2007-10-08
WO1999058142A1 (en) 1999-11-18
JP5259896B2 (ja) 2013-08-07
JP2002515404A (ja) 2002-05-28
WO1999058142A9 (en) 2000-02-10
EP1079851A1 (en) 2001-03-07
CA2328520C (en) 2013-06-25
DE69936451T2 (de) 2008-03-13
JP2012020996A (ja) 2012-02-02
US20070060520A1 (en) 2007-03-15
EP1079851A4 (en) 2004-03-17
AU3895299A (en) 1999-11-29
EP1079851B1 (en) 2007-07-04
US7115556B2 (en) 2006-10-03
ES2288777T3 (es) 2008-01-16
DE69936451D1 (de) 2007-08-16
JP5453355B2 (ja) 2014-03-26
JP2011079821A (ja) 2011-04-21
DK1079851T3 (da) 2007-09-24
EP2316467A1 (en) 2011-05-04
CA2328520A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
ATE366114T1 (de) Verwendung von anti-prolaktin agentien zur behandlung von krebs
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
PT1187918E (pt) Antagonistas de tek
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE60045751D1 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
WO2001045730A3 (en) Tweak receptor
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
WO2005023202A3 (en) Tumor suppressor lkb1 kinase directly activates amp-activated kinase
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
BG103575A (en) SUBSTITUTED NITROGENCONTAINING HETEROCYCLES AS p38 PROTEINKINASE INHIBIRORS
CZ2000531A3 (en) Method of prevention or therapy of estrogen-dependent diseases and disorders
ES2185009T3 (es) Antagonistas de alfa y beta 3'.
DE60324431D1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
ATE489103T1 (de) Gezielte thrombose durch gewebefaktor polypeptiden
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
MXPA04007443A (es) Nuevos compuestos de porfirina-platino solubles en agua con alta selectividad tumoral y su uso para el tratamiento de enfermedades tumorales benignas y malignas.
TR200200278T2 (tr) Kalsilitik bileşimler
ATE353664T1 (de) Hcg therapie zur behandlung von metastatischem brustkrebs
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1079851

Country of ref document: EP